Rabbit Anti-Human CR1 Monoclonal Antibody, clone CQ7170

Purpose Scientific information regarding the microbial content and functional aspects of fermented beverages traditionally produced in certain parts of Europe are scarce. However, such products are believed to have some health benefits and might contain functional bacterial strains, such as probiotics. The aim of the study was to identify such lactic acid bacteria strains isolated from water kefir and, for the first time, from braga, a Romanian fermented beverage made of cereals. Methods Lactic acid bacteria (LAB) were identified to species level based on (GTG)(5)-PCR fingerprinting and 16S rRNA gene sequencing. Selected strains were screened for their antibacterial activity and probiotic potential. Results Eight isolates belonging to seven Lactobacillus species were recovered from the two drinks. The identification of LAB involved in the fermentation of braga (Lactobacillus plantarum, Lactobacillus fermentum, and Lactobacillus delbrueckii) is firstly reported here. Five of the Lactobacillus isolates showed antibacterial activity against pathogenic bacteria, including Listeria monocytogenes, Escherichia coli, Staphylococcus aureus, and Salmonella enterica. Moreover, most of them showed a good resistance to pH 2.5 and some survived at high concentrations of bile salts (up to 2%). Two L. plantarum isolates were able to inhibit all the indicator strains, and showed the best viability (about 70%) after a sequential treatment simulating the passage through the gastrointestinal tract. Conclusion Based on the results, the most promising candidates for designing new probiotic products are: L. plantarum BR9 from braga and L. plantarum CR1 from water kefir.

We investigated the long-term outcome, the incidence of second neoplasms (SN) and the rate of late adverse effects (LAE) in children with central nervous system (CNS) negative medium/high-risk de novo acute lymphoblastic leukaemia (ALL), in first complete remission (CR1) at end of late intensification, randomized to receive no cranial radiotherapy (No CRT, n = 92) versus CRT (standard arm, n = 84) in the non-inferiority EORTC 58832 study (1983-1989). Median follow-up was 20 years (range 4-32 years). The 25-year disease-free survival rate (+/- SE) was 67 center dot 4 +/- 4 center dot 9% without CRT and 70 center dot 2 +/- 5 center dot 0% with CRT. The 25-year incidence of isolated (6 center dot 5 +/- 2 center dot 6% vs. 4 center dot 8 +/- 2 center dot 3%) and any CNS relapse {8 center dot 7 +/- 2 center dot 9% vs. 11 center dot 9 +/- 3 center dot 5%; hazard ratio (HR) 0 center dot 71 [95% confidence interval (CI) 0 center dot 28-1 center dot 79]; test of non-inferiority: P = 0 center dot 01} was not increased without CRT. The 25-year SN incidence in CR1 was 7 center dot 9 +/- 4 center dot 6% vs. 11 center dot 0 +/- 4 center dot 2%. The 25-year event-free and overall survival rates were quite similar in both arms [59 center dot 5 +/- 6 center dot 3% vs. 60 center dot 5 +/- 5 center dot 9%, HR 0 center dot 94 (95% CI 0 center dot 57-1 center dot 52), and 78 center dot 1 +/- 4 center dot 3% vs. 78 center dot 5 +/- 4 center dot 5%, HR 1 center dot 00 (95% CI 0 center dot 53-1 center dot 88)]. Omission of CRT was associated with dramatic decrease in CNS and endocrine LAE rates. In conclusion, our data suggest that, with proper systemic and intrathecal CNS prophylaxis, CRT could totally be omitted in CR1 without jeopardizing survival, while decreasing LAE in childhood ALL.